T. Rowe Price's Q4 2025 results show Assets Under Management at $1.62 trillion. Despite net outflows in equities, the firm saw growth in alternatives and strong fixed income performance. Adjusted EPS reached $2.44, supported by a 35.6% operating margin.

Boston Scientific reported strong FY 2025 results, with 15.8% organic revenue growth and adjusted EPS of $3.06. Success was driven by the Watchman and Electrophysiology segments. The company is expanding via acquisitions like Penumbra and new Siemens collaborations.

In 2025, The New York Times achieved record digital revenues exceeding $2 billion, adding 1.4 million subscribers. Leadership plans to scale video journalism and AI-powered products in 2026. Despite rising operating costs, the firm remains focused on margin expansion.

Yum! Brands' Q4 2025 results show strong Taco Bell momentum and record KFC international openings. Despite missing EPS estimates, revenue beat expectations. Growth is driven by the Byte digital platform, while Pizza Hut faces a strategic review and planned U.S. closures.

Clorox reported Q2 2026 results reflecting a digital transformation via a new ERP system. While net sales and gross margins dipped due to high costs and low consumption, the company is acquiring GOJO Industries to expand its health and hygiene portfolio and drive growth.

Supermicro provides modular IT and AI infrastructure through its building-block solutions. The company is scaling rack-scale manufacturing and liquid cooling technologies to support AI training. Financial reports emphasize non-GAAP metrics to track core growth and efficiency.

AMD’s Q4 2025 results surpassed expectations with $10.27 billion in revenue and $1.53 EPS. Driven by Data Center AI growth and strategic acquisitions like ZT Systems, the company expanded its instinct GPU and EPYC portfolios despite ongoing export restrictions.

Chipotle’s 2025 results show revenue growth to $11.9 billion despite a slight dip in comparable sales. The new "Recipe for Growth" strategy targets global expansion and operational efficiency. With a debt-free balance sheet, the firm continues heavy share repurchases.

In 2025, Novo Nordisk achieved 10% sales growth, reaching DKK 309 billion, primarily driven by a 31% surge in obesity care. Key developments include the Wegovy pill launch and pipeline assets like CagriSema. The firm announced a DKK 15 billion share buyback and increased dividends.

Chubb reported record earnings for Q4 2025, with core operating income rising to $2.98 billion. Strong underwriting performance led to a record low combined ratio of 81.2%. Growth was driven by P&C premiums and life insurance, particularly in international consumer markets.